CYP2D6 GENOTYPE DETERMINATION IN THE DANISH POPULATION

被引:39
作者
BROSEN, K [1 ]
NIELSEN, PN [1 ]
BRUSGAARD, K [1 ]
GRAM, LF [1 ]
SKJODT, K [1 ]
机构
[1] ODENSE UNIV,INST MED BIOL,DEPT MED MICROBIOL,DK-5000 ODENSE,DENMARK
关键词
SPARTEINE-OXIDATION; GENETIC POLYMORPHISM; CYP2D6; GENOTYPING; XBA1; RFLP-PCR; DANISH POPULATION;
D O I
10.1007/BF02570501
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
CYP2D6 genotyping was carried out by XbaI restriction fragment length polymorphism analysis and polymerase chain reaction in 168 healthy Danish volunteers, 77 extensive metabolizers (EM) and 91 poor metabolizers (PM) of sparteine. All EM were genotyped correctly as heterozygous or homozygous for the functional (wild type) gene, DG-wt. However, the DG-wt gene was apparently also present in 11 (12%) of the PM who accordingly were incorrectly genotyped as EM. The specificity of genotyping PM thus was 100% but the sensitivity was only 88%. The most common allele was the DG-wt with an apparent frequency of 0.741 (0.026) in the Danish population and the second most common allele was the D6-B with an apparent frequency of 0.194 (0.024). The median (range) of the sparteine metabolic ratio (MR) in 47 homozygous D6-wt EM was 0.28 (0.11-4.10) and the corresponding value in heterozygous EM was 0.36 (0.11-9.10). The median difference was 0.09 (95% confidence interval: 0.02-0.16). CYP2D6 phenotyping is a promising tool in tailoring the individual dose of tricyclic antidepressants, some neuroleplics and some antiarrhythmics. However if the genotype test could be improved with regard to both sensitivity in PM and the ability to predict CYP2D6 activity in EM then it would be of even greater clinical value in therapeutic drug monitoring.
引用
收藏
页码:221 / 225
页数:5
相关论文
共 38 条
  • [1] DEBRISOQUIN OXIDATION GENOTYPE AND SUSCEPTIBILITY TO LUNG-CANCER
    AGUNDEZ, JAG
    MARTINEZ, C
    LADERO, JM
    LEDESMA, MC
    RAMOS, JM
    MARTIN, R
    RODRIGUEZ, A
    JARA, C
    BENITEZ, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (01) : 10 - 14
  • [2] HYDROXYLATION POLYMORPHISMS OF DEBRISOQUINE AND MEPHENYTOIN IN EUROPEAN POPULATIONS
    ALVAN, G
    BECHTEL, P
    ISELIUS, L
    GUNDERTREMY, U
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (06) : 533 - 537
  • [3] DEBRISOQUINE OXIDATION POLYMORPHISM - PHENOTYPIC CONSEQUENCES OF A 3-BASE-PAIR DELETION IN EXON 5 OF THE CYP2D6 GENE
    BROLY, F
    MEYER, UA
    [J]. PHARMACOGENETICS, 1993, 3 (03): : 123 - 130
  • [4] DEBRISOQUINE SPARTEINE HYDROXYLATION GENOTYPE AND PHENOTYPE - ANALYSIS OF COMMON MUTATIONS AND ALLELES OF CYP2D6 IN A EUROPEAN POPULATION
    BROLY, F
    GAEDIGK, A
    HEIM, M
    EICHELBAUM, M
    MORIKE, K
    MEYER, UA
    [J]. DNA AND CELL BIOLOGY, 1991, 10 (08) : 545 - 558
  • [5] BROSEN K, 1985, ACTA PHARMACOL TOX, V57, P357
  • [6] SPARTEINE OXIDATION POLYMORPHISM - A FAMILY STUDY
    BROSEN, K
    OTTON, SV
    GRAM, LF
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 21 (06) : 661 - 667
  • [7] EXTREMELY SLOW METABOLISM OF AMITRIPTYLINE BUT NORMAL METABOLISM OF IMIPRAMINE AND DESIPRAMINE IN AN EXTENSIVE METABOLIZER OF SPARTEINE, DEBRISOQUINE, AND MEPHENYTOIN
    BROSEN, K
    GRAM, LF
    KRAGHSORENSEN, P
    [J]. THERAPEUTIC DRUG MONITORING, 1991, 13 (02) : 177 - 182
  • [8] BROSEN K, 1993, CLIN INVESTIGATOR, V71, P1002
  • [9] CLINICAL-SIGNIFICANCE OF THE SPARTEINE-DEBRISOQUINE OXIDATION POLYMORPHISM
    BROSEN, K
    GRAM, LF
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (06) : 537 - 547
  • [10] Brosen K, 1993, Psychopharmacol Ser, V10, P199